RxDoctor Payments Data

Kalyani Avva, DO

Internal Medicine · Dallas, TXNPI 1942863303

Payments from drug & device makers

$346in general payments, 2019–2025

Across 14 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$89
  • Dexcom, Inc.$75
  • CSL Behring$63
  • Tetraphase Pharmaceuticals, Inc.$31
  • Novartis$29
  • Johnson & Johnson$28
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$346 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,233
Medicare patients
159
Services billed
1,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$49,442
JardianceEmpagliflozin24$35,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$23,945
JanuviaSitagliptin Phosphate14$22,858
EliquisApixaban20$22,541
XareltoRivaroxaban14$20,193
FarxigaDapagliflozin Propanediol20$14,896
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$7,288
SymbicortBudesonide/Formoterol Fumarate17$7,018
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,794
Levothyroxine Sodium188$2,082
Wixela InhubFluticasone Propion/Salmeterol11$1,696
LantusInsulin Glargine,hum.Rec.Anlog11$1,435
Omeprazole77$1,233
Albuterol Sulfate HfaAlbuterol Sulfate46$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$89$23,94526 claims
PfizerEliquis$12$22,54120 claims
Johnson & JohnsonXarelto$28$20,19314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →